VANCOUVER, BRITISH COLUMBIA--(Marketwire - Dec 6, 2012) - Verisante Technology, Inc. (TSX VENTURE:VRS)(VRSEF) (the "Company" or "Verisante"), a leader in cancer detection technology, announced today that the early appearance model and sketches of the development of Verisante Aura™ will be exhibited at the Canada Science and Technology Museum in Ottawa for six months and will remain as part of the Museum''s permanent collection thereafter.
An exhibit entitled "Curator''s Corner," which opened to the public on December 4, 2012, showcases Aura''s™ early prototyping development.
"With over 300,000 visitors to the Museum each year, this is a great honour and opportunity to share some of our early development work with Canadians," said Thomas Braun, President and CEO. "Visitors to the Museum will be able to learn about Aura™, see the conceptual development of the design of the device, and then go to their dermatologist and request an Aurascan™ with the final production device."
"We are very grateful to Verisante Technology for the opportunity to exhibit Verisante Aura™ at the Canada Science and Technology Museum," said Canada Science and Technology Museums Corporation (CSTMC) CEO Denise Amyot. "Verisante Technology is a great example of leadership in Canadian research and innovation, and we always welcome new ways of telling the public about the compelling stories of success and achievement in the Canadian science and technology sectors."
About the Canada Science and Technology Museum
The largest of its kind in Canada, the Museum fulfills its mission through its collection, permanent, temporary and travelling exhibits, special events, school programs, workshops and demonstrations, publications, loans, conferences and lectures, expert advice, and joint action with other museums and organizations with similar goals and interests.
The role of the Museum is to help the public to understand the technological and scientific history of Canada and the ongoing relationships between science, technology and Canadian society. The artifacts present the ongoing relationships between science, technology, and the transformation of Canadian society.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. The Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine''s "Best of What''s New Award" for 2011, and Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society. In addition, the Company was named a finalist for the 2011 Regional Awards for New Technology by the Canadian Manufacturers & Exporters and the National Research Council of Canada and named as the year''s top ranking Technology and Life Sciences Company on the TSX Venture 50.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.